Related references
Note: Only part of the references are listed.Comparison of the Immunogenicity and Reactogenicity of Cervarix and Gardasil Human Papillomavirus Vaccines in HIV-Infected Adults: A Randomized, Double-Blind Clinical Trial
Lars Toft et al.
JOURNAL OF INFECTIOUS DISEASES (2014)
High-throughput SNP-based authentication of human cell lines
Felipe Castro et al.
INTERNATIONAL JOURNAL OF CANCER (2013)
Natural variants in the major neutralizing epitope of human papillomavirus minor capsid protein L2
Hanna Seitz et al.
INTERNATIONAL JOURNAL OF CANCER (2013)
High-Throughput Pseudovirion-Based Neutralization Assay for Analysis of Natural and Vaccine-Induced Antibodies against Human Papillomaviruses
Peter Sehr et al.
PLOS ONE (2013)
Safety and immunogenicity of the HPV-16/18 AS04-adjuvanted vaccine in HIV-positive women in South Africa: A partially-blind randomised placebo-controlled study
Lynette Denny et al.
VACCINE (2013)
Cross-protective vaccine efficacy of the bivalent HPV vaccine against HPV31 is associated with humoral immune responses Results from the Costa Rica vaccine trial
Mahboobeh Safaeian et al.
HUMAN VACCINES & IMMUNOTHERAPEUTICS (2013)
Humoral, Mucosal, and Cell-Mediated Immunity Against Vaccine and Nonvaccine Genotypes After Administration of Quadrivalent Human Papillomavirus Vaccine to HIV-Infected Children
Adriana Weinberg et al.
JOURNAL OF INFECTIOUS DISEASES (2012)
Cross-protective efficacy of two human papillomavirus vaccines: a systematic review and meta-analysis
Talia Malagon et al.
LANCET INFECTIOUS DISEASES (2012)
Cross-protective efficacy of HPV-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial
Cosette M. Wheeler et al.
LANCET ONCOLOGY (2012)
End-of-study safety, immunogenicity, and efficacy of quadrivalent HPV (types 6, 11, 16, 18) recombinant vaccine in adult women 24-45 years of age
X. Castellsague et al.
BRITISH JOURNAL OF CANCER (2011)
Comparison of the immunogenicity of the human papillomavirus (HPV)-16/18 vaccine and the HPV-6/11/16/18 vaccine for oncogenic non-vaccine types HPV-31 and HPV-45 in healthy women aged 18-45 years
Mark H. Einstein et al.
HUMAN VACCINES (2011)
Efficacy of Quadrivalent HPV Vaccine against HPV Infection and Disease in Males
Anna R. Giuliano et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
HPV Vaccine against Anal HPV Infection and Anal Intraepithelial Neoplasia
Joel M. Palefsky et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Immunosuppressive disorders and risk of anal squamous cell carcinoma: a nationwide cohort study in Denmark, 1978-2005
Kare G. Sunesen et al.
INTERNATIONAL JOURNAL OF CANCER (2010)
Safety and Immunogenicity of a Quadrivalent Human Papillomavirus (Types 6, 11, 16, and 18) Vaccine in HIV-Infected Children 7 to 12 Years Old
Myron J. Levin et al.
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES (2010)
Safety and Immunogenicity of the Quadrivalent Human Papillomavirus Vaccine in HIV-1-Infected Men
Timothy Wilkin et al.
JOURNAL OF INFECTIOUS DISEASES (2010)
Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study
Silvia de Sanjose et al.
LANCET ONCOLOGY (2010)
Evaluation of quadrivalent HPV 6/11/16/18 vaccine efficacy against cervical and anogenital disease in subjects with serological evidence of prior vaccine type HPV infection
Sven-Eric Olsson et al.
HUMAN VACCINES (2009)
The Impact of Quadrivalent Human Papillomavirus (HPV; Types 6, 11, 16, and 18) L1 Virus-Like Particle Vaccine on Infection and Disease Due to Oncogenic Nonvaccine HPV Types in Sexually Active Women Aged 16-26 Years
Cosette M. Wheeler et al.
JOURNAL OF INFECTIOUS DISEASES (2009)
The Impact of Quadrivalent Human Papillomavirus (HPV; Types 6, 11, 16, and 18) L1 Virus-Like Particle Vaccine on Infection and Disease Due to Oncogenic Nonvaccine HPV Types in Generally HPV-Naive Women Aged 16-26 Years
Darron R. Brown et al.
JOURNAL OF INFECTIOUS DISEASES (2009)
Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women
J. Paovonen et al.
LANCET (2009)
High-throughput detection and multiplex identification of cell contaminations
Markus Schmitt et al.
NUCLEIC ACIDS RESEARCH (2009)
Dermatologic manifestations of HPV in HIV-infected individuals
Rachel H. Gormley et al.
Current HIV/AIDS Reports (2009)
Marked increase on the incidence of invasive anal cancer among HIV-infected patients despite treatment with combination antiretroviral therapy
Christophe Piketty et al.
AIDS (2008)
Incidence of types of cancer among HIV-Infected persons compared with the general population in the United States, 1992-2003
Pragna Patel et al.
ANNALS OF INTERNAL MEDICINE (2008)
Human papillomavirus types 16 and 18 vaccine (Recombinant, AS04 adjuvanted, adsorbed) [Cervarix (TM)]
Susan J. Keam et al.
DRUGS (2008)
Human papillomavirus and cervical cancer
Mark Schiffman et al.
LANCET (2007)
Quadrivalent human papillomavirus vaccine
Eliav Barr et al.
CLINICAL INFECTIOUS DISEASES (2007)
Incidence of cancers in people with HIV/AIDS compared with immunosuppressed transplant recipients: a meta-analysis
Andrew E. Grulich et al.
LANCET (2007)
Human papillomavirus quadrivalent (types 6, 11, 16, 18) recombinant vaccine (Gardasil (R))
M. Asif A. Siddiqui et al.
DRUGS (2006)
Human papillomavirus infection and disease in HIV-infected individuals
ME Hagensee et al.
AMERICAN JOURNAL OF THE MEDICAL SCIENCES (2004)
The causal relation between human papillomavirus and cervical cancer
FX Bosch et al.
JOURNAL OF CLINICAL PATHOLOGY (2002)
Relapses after treatment of external genital warts are more frequent in HIV-positive patients than in HIV-negative controls
G De Panfilis et al.
SEXUALLY TRANSMITTED DISEASES (2002)
Share Paper
